Erasca, Inc.
ERASNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$140.9M | −$179.6M | −$141.5M | −$247.4M | −$124.9M | −$109.3M |
| Net income | −$124.5M | −$161.7M | −$125.0M | −$242.8M | −$122.8M | −$101.7M |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M | $124.8M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M | $17.4M |
| Equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M | −$114.0M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 | — |
| Shares out. | 283.3M | 151.5M | 150.6M | 121.6M | 119.1M | 21.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −38.3%
- Return on assets
- −31.4%
- Return on capital (ROCE)
- −38.3%
- Liabilities / assets
- 17.9%
- Debt / equity
- 0.22×
- Book value / share
- $1.15
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.65distress
- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2025-05-01A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1Active Not Recruitingreadout ~2025-07-01A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
- Phase 1Active Not Recruitingreadout ~2026-02-01A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
- Phase 3Active Not Recruitingreadout ~2028-04A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
- Phase 1Recruitingreadout ~2028-05-01A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1Recruitingreadout ~2028-08A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)May 15, 2026
- Rtw Investments, LpPassive (13G)May 15, 2026
- Paradigm Biocapital Advisors LpPassive (13G)May 15, 2026
- Suvretta Capital Management, LlcPassive (13G)May 12, 2026
- Logos Global Management LpPassive (13G)Nov 14, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Aug 14, 2025
- Novartis Pharma AgPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Garner EbunOfficer — Chief Legal Officer | Apr 1, 2026 | Option exercise | 80,000 | $1.70 |
| Morris ShannonOfficer — Chief Medical Officer | Mar 4, 2026 | Option exercise | 20,000 | $1.70 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 31.4M | 6.7 | -2.0% |
| Apr 30, 2026 | 32.1M | 2.4 | -5.7% |
| Apr 15, 2026 | 34.0M | 6.1 | +13.7% |
| Mar 31, 2026 | 29.9M | 4.8 | +13.5% |
| Mar 13, 2026 | 26.3M | 5.5 | -3.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Other material eventApr 27, 2026
- Regulation FD disclosure · Other material eventApr 27, 2026
- Other material eventApr 21, 2026
- Results of operationsMar 12, 2026
- Other material eventJan 29, 2026
- Other material eventJan 22, 2026
- Results of operationsJan 20, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 144May 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 12, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- 8-KApr 27, 2026
- 8-KApr 27, 2026
- 8-KApr 21, 2026
- 144/AApr 15, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.